Selventa

Genstruct and Gene Logic Collaborate on Systems Toxicology

Genstruct and Gene Logic Collaborate on Systems Toxicology

February 25, 2009

SAN FRANCISCO, Calif., CAMBRIDGE, Mass. and Gaithersburg, Md., February 25, 2009 – (CHI’s Molecular Medicine Tri-Conference) - Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that it has signed a partnership agreement with Gene Logic, an Ocimum Biosolutions company, for a systems toxicology collaboration.

Mascoma Corporation

Mascoma Cellulosic Ethanol Plant Begins Operations in Rome, NY

Mascoma Cellulosic Ethanol Plant Begins Operations in Rome, NY

February 25, 2009

Facility Generating Biomass-based Ethanol With Assistance from New York State Agencies

Boston, MA – February 25, 2009: Mascoma Corporation, a leader in the development of low carbon cellulosic ethanol, today announced that the company’s demonstration facility in Rome, New York, is now producing ethanol from non-food cellulosic biomass.

BG Medicine, Inc.

BG Medicine Appoints Doug White as Executive Vice President & General Manager, Diagnostics

BG Medicine Appoints Doug White as Executive Vice President & General Manager, Diagnostics

March 3, 2009

Waltham, Mass. – BG Medicine Inc. (BGM) today announced that Doug White has joined the organization as Executive Vice President & General Manager, Diagnostics. In this newly created role, Mr. White will be responsible for the strategic direction and overall management of the company’s commercial operations as it advances a broad portfolio of high-value diagnostic tests toward commercial launch.

Seahorse Bioscience, Inc.

Seahorse Bioscience, Inc. acquires BioProcessors Corp.

Seahorse Bioscience, Inc. acquires BioProcessors Corp.

March 9, 2009

Market Vision, Engineering Know-how, and Smart Plastics Expertise Combine to bring Practical Cell Technologies to the Life Sciences

N. Billerica, MA – March 9, 2009 - Seahorse Bioscience, Inc., manufacturer of instruments and consumables for cell based metabolic assays today announced the acquisition of BioProcessors Corp., manufacturer of systems for optimizing biologic drug manufacturing. The two companies will be integrated and operate under the Seahorse name.

BG Medicine, Inc.

BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University

BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University

March 12, 2009

Biosamples from the Framingham Heart Study will be used to Discover New Blood Tests for Heart Disease

WALTHAM, Mass., March 12 /PRNewswire/ -- BG Medicine, a biotechnology company focused on the discovery and development of novel diagnostic biomarkers, today announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and Boston University (BU).

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347

Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347

March 16, 2009

First Clinical Demonstration of Concert’s Technology Platform

BG Medicine, Inc.

BG Medicine Inc. launches Galectin-3 Website and Commences Galectin-3 Assay Service for Clinical Research

BG Medicine Inc. launches Galectin-3 Website and Commences Galectin-3 Assay Service for Clinical Research

April 1, 2009

WALTHAM, Mass. – (BUSINESS WIRE) - BG Medicine Inc. (BGM), a developer of novel,biomarker-based diagnostic products, today announced the launch of the Galectin-3 Website (www.galectin-3.com) which will provide an array of research materials associated with galectin-3.

Ensemble Therapeutics Corporation

Ensemble Discovery Initiates Collaboration with Bristol-Myers Squibb to Develop Drugs in Novel Therapeutic Class

Ensemble Discovery Initiates Collaboration with Bristol-Myers Squibb to Develop Drugs in Novel Therapeutic Class

April 15, 2009

Alliance will deploy EnsemblinTM platform to access new therapeutic opportunities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Discovery today announced the initiation of a strategic alliance with Bristol-Myers Squibb Company (NYSE: BMY) to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.

VisEn Medical, Inc.

VisEn Launches Next-Generation FAST (“Fluorescence Activatible Sensor Technology”) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

VisEn Launches Next-Generation FAST (“Fluorescence Activatible Sensor Technology”) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

April 20, 2009

MMPSense™ 750 FAST is Presented at AACR 100th Annual Meeting

Acceleron Pharma, Inc.

Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters and Manufacturing Facility

Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters and Manufacturing Facility

May 1, 2009

Lt. Governor Murray and other Massachusetts Dignitaries on Hand to Celebrate Rapid Growth of Acceleron Product Pipeline and Plans to Further Increase Workforce